IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other CNS disorders. The company develops Mesdopetam that is in phase IIb clinical studies for the treatment of levodopa-induced dyskinesia; and Pirepemat, which is in phase IIb clinical trial indicated for the treatment of falls frequency, postural dysfunction, cognitive function, and symptoms … Read more
IRLAB Therapeutics AB (publ) - Asset Resilience Ratio
IRLAB Therapeutics AB (publ) (IRLAB-A) has an Asset Resilience Ratio of 64.58% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how IRLAB Therapeutics AB (publ)'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down IRLAB Therapeutics AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr110.13 Million | 64.58% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr110.13 Million | 64.58% |
Asset Resilience Insights
- Very High Liquidity: IRLAB Therapeutics AB (publ) maintains exceptional liquid asset reserves at 64.58% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
IRLAB Therapeutics AB (publ) Industry Peers by Asset Resilience Ratio
Compare IRLAB Therapeutics AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for IRLAB Therapeutics AB (publ) (2016–2024)
The table below shows the annual Asset Resilience Ratio data for IRLAB Therapeutics AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 49.13% | Skr66.92 Million | Skr136.21 Million | -13.72pp |
| 2023-12-31 | 62.84% | Skr111.31 Million | Skr177.12 Million | -15.28pp |
| 2022-12-31 | 78.12% | Skr252.78 Million | Skr323.56 Million | -6.94pp |
| 2021-12-31 | 85.07% | Skr401.90 Million | Skr472.45 Million | +10.21pp |
| 2020-12-31 | 74.85% | Skr277.01 Million | Skr370.07 Million | +21.73pp |
| 2019-12-31 | 53.12% | Skr110.53 Million | Skr208.07 Million | -6.65pp |
| 2018-12-31 | 59.77% | Skr134.44 Million | Skr224.94 Million | +13.93pp |
| 2017-12-31 | 45.84% | Skr74.71 Million | Skr162.97 Million | +23.09pp |
| 2016-12-31 | 22.75% | Skr25.74 Million | Skr113.11 Million | -- |